STAT6 inhibitors
The present disclosure provides compounds that are useful for inhibiting the STAT6 pathway. Also provided are related pharmaceutical compositions and methods of using the compounds. In some embodiments, the compounds may be used to treat a disease such as, e.g., an allergic lung disease, allergic rhinitis, chronic pulmonary obstructive disease, or a cancer.
1. A compound of the formula:
wherein:
R 21 is phosphate, —OP(O)(OR 10 )(OR 10′ ), -alkyl (C1-6) -P(O)(OR 10 )(OR 10′ ), or a substituted version of any of these groups; wherein
R 10 and R 10′ are each independently hydrogen, alkyl (C1-6) , aryl (C6-8) , aralkyl (C7-12) , alkyl (C1-6) -O—C(O)-alkyl (C1-6) , alkyl (C1-6) -O—C(O)-aryl (C6-8) , or
wherein m=1-8; wherein X is —CH 2 —, —O—, —S—, or —NH—; provided that R 10 and R 10′ are not both hydrogen;
R 22 is hydrogen or alkyl (C1-6) ;
R 23 is hydrogen, alkyl (C1-12) , or aryl (C6-12) ;
R 24 is aryl (C≤12) ;
wherein if an alkyl, aryl, or aralkyl group is substituted then one or more hydrogen atom on the alkyl, aryl or aralkyl group has been independently replaced by —OH, —F, —Cl, —Br, —I, —NH 2 , —NO 2 , —CO 2 H, —CO 2 CH 3 , —CN, —SH, —OCH 3 , —OCH 2 CH 3 , —C(O)CH 3 , —NHCH 3 , —NHCH 2 CH 3 , —N(CH 3 ) 2 , —C(O)NH 2 , —OC(O)CH 3 , or —S(O) 2 NH 2 ;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein the R 21 is -alkyl (C1-6) -P(O)(OR 10 )(OR 10′ ) or substituted -alkyl (C1-6) -P(O)(OR 10 )(OR)(OR 10′ ).
3. The compound of claim 2 , wherein R 21 is —CF 2 —P(O)(OCH 2 OC(O)C(CH 3 ) 3 ) 2 .
4. The compound of claim 1 , wherein R 22 is hydrogen.
5. The compound of claim 1 , wherein R 23 is aryl (C6-12) .
6. The compound of claim 5 , wherein R 23 is phenyl.
7. The compound of claim 1 , wherein R 24 is aryl (C8-C12) .
8. The compound of claim 7 , wherein R 24 is biphenyl.
9. The compound of claim 1 , wherein the compound has the formula:
or a pharmaceutically acceptable salt thereof.
10. A pharmaceutical composition comprising an effective amount of a compound of formula (I) of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
11. The pharmaceutical composition of claim 10 , wherein the pharmaceutical composition is formulated for oral, intravenous, intranasal, or inhalational administration.
12. The pharmaceutical composition of claim 11 , wherein the pharmaceutical composition is comprised in a nebulizer, an inhaler, or a nasal spray.
13. The pharmaceutical composition of claim 12 , wherein the pharmaceutical composition further comprises a bronchodialator.
14. The pharmaceutical composition of claim 13 , wherein the bronchodialator is a long-acting β2 agonist.
15. A method of treating an allergic or inflammatory lung disease in a subject comprising administering to the subject a therapeutically effective amount of a compound of claim 1 to the subject.
16. The method of claim 15 , wherein the lung disease is asthma or airway hyperresponsiveness.
17. The method of claim 15 , wherein the lung disease is an allergic disease, allergic rhinitis, emphysema, chronic obstructive pulmonary disease (COPD), reactive airway disease, or chronic rhinosinusitis.
18. The method of claim 15 , further comprising administering to the subject a second therapeutic compound to the subject.
19. The method of claim 18 , wherein the second therapeutic compound is a bronchodialator, an anti-inflammatory steroid, an antihistamine, or an anti-fungal antibiotic.
20. The method of claim 19 , wherein the second therapeutic compound is a bronchodialator, and wherein the bronchodialator is a short-acting β-2 agonist, a long-acting β2 agonist, or an anticholinergic.
21. A method of inhibiting STAT6 in a subject comprising administering to the subject a compound of claim 1 to the subject in an amount an effective to inhibit STAT6, wherein the subject has lung inflammation.
22. The compound of claim 1 , wherein R 23 is hydrogen or alkyl (C1-12) .